Research programme: brain disease therapeutics - Lundbeck/Janssen
Latest Information Update: 07 Jan 2015
At a glance
- Originator Janssen; Lundbeck A/S
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Alzheimer's disease; Depressive disorders
Most Recent Events
- 22 Dec 2014 Early research in Depressive disorders in Europe (unspecified route)
- 22 Dec 2014 Early research in Alzheimer's disease in Europe (unspecified route)